Patents Assigned to Merck
  • COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20230338498
    Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae.
    Type: Application
    Filed: March 23, 2023
    Publication date: October 26, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Chitrananda Abeygunawardana, Yadong Adam Cui, Romulo Ferrero, Jian He, Luwy Musey, Tanaz Petigara, Julie M. Skinner
  • METHODS OF TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, A CHEMORADIATION THERAPY AND A PARP INHIBITOR
    Publication number: 20230338521
    Abstract: Provided herein are methods of treating cancer using a combination of (a) one or more programmed death 1 protein (PD-1) antagonists, (b) a radiotherapy, (c) one or more poly (ADP-ribose) polymerase (PARP) inhibitor, and optionally, (d) one or more chemotherapies. Also provided herein is a kit for pharmaceutical administration comprising: (a) a PD-1 antagonist; (b) a radiotherapy; (c) a PARP inhibitor; and (d) optionally, a chemotherapy. Further provided herein are uses of a combination for treating cancer in a human patient, wherein the combination comprises: (a) an effective amount of one or more PD-1 antagonists, (b) an effective amount of a radiotherapy, (c) an effective amount of a PARP inhibitor, and (d) optionally, one or more chemotherapies.
    Type: Application
    Filed: April 29, 2021
    Publication date: October 26, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Roger M. Perlmutter, Maria Catherine Pietanza
  • POLYMERIZABLE LIQUID CRYSTAL MATERIAL AND POLYMERIZED LIQUID CRYSTAL FILM
    Publication number: 20230340329
    Abstract: The invention relates to a polymerizable LC material comprising one or more reactive mesogenic compounds, one or more chiral compounds and one or more compounds of formula I, wherein the individual radicals have one of the meaning as given in the claims. Furthermore, the present invention relates also to a method for its preparation, a polymer film with improved thermal and UV stability obtainable from a corresponding polymerizable LC material, to a method of preparation of such polymer film, and to the use of such polymer film and said polymerizable LC material in optical, electro-optical, decorative or security devices.
    Type: Application
    Filed: September 23, 2021
    Publication date: October 26, 2023
    Applicant: Merck Patent GmbH
    Inventors: Stephen MULCAHY, Owain Llyr PARRI, Sarabjot KAUR
  • Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
    Patent number: 11793821
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: October 24, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey
  • Dual UV blockers containing stable photoactive mass polymerizable polycycloolefin compositions as optical materials
    Patent number: 11795285
    Abstract: Embodiments in accordance with the present invention encompass compositions encompassing a latent organo-ruthenium compound, a photosensitizer, one or more monomers which undergo ring open metathesis polymerization (ROMP) and at least two distinct types of UV blockers, where when said composition is exposed to suitable actinic radiation forms a substantially transparent film or a three dimensional object. Surprisingly, the compositions are very stable at ambient conditions to temperatures up to 80° C. for several weeks and undergo mass polymerization only when subjected to actinic radiation under inert atmosphere such as for example a blanket of nitrogen. Accordingly, compositions of this invention are useful in various opto-electronic applications, including as 3D printing materials, coatings, encapsulants, fillers, leveling agents, among others.
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: October 24, 2023
    Assignees: Promerus, LLC, Merck Patent GmbH
    Inventors: Oleksandr Burtovyy, Pawel Miskiewicz, Hyun-Jin Yoon, Patrick Schellin, Manuel Hamburger
  • Sanitation assembly and method
    Patent number: 11793898
    Abstract: A sanitation assembly (1) comprising a first chamber (2) with a first volume (2a) for receiving a first fluid, and a second chamber (3) with a second volume (3a) for receiving a second fluid, wherein the first volume (2a) communicates with an outlet (6) of the assembly (1) via a first valve mechanism (4) configured to allow discharge of the fluid from the first volume (2a) to the outlet (6) at a predefined first opening pressure, wherein the second volume (3a) communicates with the outlet (6) of the assembly (1) via a second valve mechanism (5) configured to allow discharge of the fluid from the second volume (3a) to the outlet (6) at a predefined second opening pressure, and wherein the predefined second opening pressure of the second valve mechanism (5) is higher than the predefined first opening pressure of the first valve mechanism (4).
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: October 24, 2023
    Assignee: Merck Patent GmbH
    Inventor: Fabrice Comini
  • Liquid-crystalline medium and liquid-crystal display comprising the same and compounds
    Patent number: 11795398
    Abstract: The invention relates to a liquid-crystalline medium having a nematic phase comprising one or more compounds of formula X wherein the parameters have the meaning given in the text, to the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type and to the use of the compounds of formula X for improvement of the transmission and/or response times of a liquid-crystalline medium which comprises one or more additional mesogenic compounds, as well as to the compounds of formula X.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: October 24, 2023
    Assignee: MERCK PATENT GMBH
    Inventors: Atsutaka Manabe, Constanze Brocke, Brigitte Schuler
  • UV curable adhesion promoters based on functionalised polyvinyl alcohols
    Patent number: 11795399
    Abstract: Suggested are new adhesion promoters, which are particular suitable for use in displays. Its inclusion in the polymerisable LC mixture results in an excellent adhesion on substrate without colouration over time i.e. compared to amino siloxanes. The new additives have no effect on alignment of LC on the substrate while improving the adhesion.
    Type: Grant
    Filed: September 4, 2017
    Date of Patent: October 24, 2023
    Assignee: MERCK PATENT GMBH
    Inventors: Hassan Arasi, Kevin Adlem, Stephen Mulcahy, Iain Gardiner
  • MEROXAPOLS FOR CELL CULTURE
    Publication number: 20230332100
    Abstract: The present invention relates to the use of meroxapols, also called “reverse poloxamers”, as cell culture media additives. The meroxapols are suitable for foam reduction as well as for shear stress protection.
    Type: Application
    Filed: April 12, 2023
    Publication date: October 19, 2023
    Applicant: MERCK PATENT GMBH
    Inventors: Alice ANTONELLO, Tim Hofmann, Almut RAPP
  • LAG3 ANTAGONIST CELL BASED POTENCY ASSAY
    Publication number: 20230333090
    Abstract: The present disclosure describes a murine T cell 3A9 comprising a polynucleotide sequence encoding human LAG3, and a murine IL-2 promotor operably associated with a reporter gene. The disclosure also describes a cell-based potency assay for measuring LAG3 antagonist activity using a co-cultured system with the murine T cells and LK35.2 murine B cells, and hen egg lysozyme peptide.
    Type: Application
    Filed: December 16, 2020
    Publication date: October 19, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kevin B. Gurney, Yue Zhang, Linda Liang, Cuiwei Ai
  • PHARMACEUTICAL PREPARATION
    Publication number: 20230330027
    Abstract: The present invention relates to a solid pharmaceutical preparation of of 8-(1,3-Dimethyl-1 H-pyrazol-4-yl)-1-(Sa)-(3-fluoro-5-methoxy-pyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, as well as a method of making same, as well as medical uses thereof.
    Type: Application
    Filed: September 15, 2021
    Publication date: October 19, 2023
    Applicant: MERCK PATENT GMBH
    Inventors: Alessandra AMBRUOSI, Riccardo MANNINI, Markus RIEHL, Axel BECKER
  • Connecting mechanism for a water purification cartridge
    Patent number: 11786867
    Abstract: A connecting mechanism (1) for a cartridge-type replaceable module (2) that has at least one fluid port (2a,2b) at each of opposite sides of the module (2) in a longitudinal direction of the module (2). The connecting mechanism (1) comprises two connector elements (3) spaced apart in the longitudinal direction of the module (2) and each provided with at least one fluid connector (3b) configured to releasably inter-engage with a complementary fluid port (2a,2b) of the module (2) at the respective side thereof, wherein at least one of the connector elements (3) is movable to perform a translational movement in the longitudinal direction of the module (2).
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: October 17, 2023
    Assignee: Merck Patent GmbH
    Inventors: Pascal Roitel, Germain Gaydier, Thierry Cassou, Christian Berducat
  • Diacylglyceride O-acyltransferase 2 inhibitors
    Patent number: 11787810
    Abstract: Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: October 17, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Yeon-Hee Lim, Cedric Lorenz Hugelshofer, Victor W. Mak, James Patrick Roane, Jillian R. Sanzone, Samantha E. Shockley, Rose Yen
  • Liquid-crystalline medium for use in a switching element
    Patent number: 11788009
    Abstract: Liquid-crystalline media containing one or more mesogenic compounds, one or more chiral compounds, and one or more polymerizable mesogenic compounds, wherein the media exhibit a pitch of 0.55 ?m or more and a clearing point of 80° C. or more and wherein the one or more polymerizable mesogenic compounds are contained in an amount, based on the overall contents of the media, of 5% by weight or less, are suitable as modulation materials. Such modulation materials can be used in switching layers and window elements.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: October 17, 2023
    Assignee: MERCK PATENT GMBH
    Inventors: Paul Verbunt, Ties De Jong, Michael Junge, Mila Fischer
  • STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230321234
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti- PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
    Type: Application
    Filed: March 10, 2023
    Publication date: October 12, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, William P. Forrest, Jr., Yogita Krishnamachari
  • ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY
    Publication number: 20230322785
    Abstract: The present invention provides compounds of the structural Formula (I) and pharmaceutically acceptable salts thereof, wherein, are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.
    Type: Application
    Filed: July 21, 2022
    Publication date: October 12, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Amjad Ali, Christopher W. Boyce, Jared N. Cumming, Duane DeMong, Thomas H. Graham, Subrahmanyam Gudipati, Andrew J. Hoover, Xianhai Huang, Rongze Kuang, Jae-Hun Kim, Joseph M. Kelly, Yeon-Hee Lim, Michael Man-Chu Lo, Jesus Moreno, Jing Su, Heping Wu, Dong Xiao, Younong Yu, Xiaohong Zhu
  • LIQUID-CRYSTALLINE MEDIUM
    Publication number: 20230323207
    Abstract: The present invention relates to a liquid-crystal material (LC media) comprising thiophene derivatives which are stabilised by sterically hindered amines or amine derivatives (HALS, hindered amine light stabilisers), and to liquid-crystal displays (LC displays) which contain these LC materials.
    Type: Application
    Filed: April 11, 2023
    Publication date: October 12, 2023
    Applicant: MERCK PATENT GMBH
    Inventors: Atsutaka MANABE, Rocco FORTTE, Harald HIRSCHMANN
  • ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERS
    Publication number: 20230322934
    Abstract: A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-?v integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.
    Type: Application
    Filed: October 28, 2022
    Publication date: October 12, 2023
    Applicant: Merck Patent GmbH
    Inventors: Ilhan CELIK, Eike Staub, Miriam Urban, Sabine Raab-Westphal, Eileen Samy, Andrew Bender, Georgianna Varrone, Yin Wu, Daigen Xu
  • LIQUID-CRYSTAL MEDIUM
    Publication number: 20230323209
    Abstract: The present invention relates to liquid-crystal (LC) media as defined in claim 1, having negative dielectric anisotropy and to the use thereof for optical, electro-optical and electronic purposes, in particular in LC displays.
    Type: Application
    Filed: April 11, 2023
    Publication date: October 12, 2023
    Applicant: MERCK PATENT GMBH
    Inventor: Jing WANG
  • Calibration device for an optical detector and setting device for setting calibration points for the calibration device
    Patent number: 11785683
    Abstract: The present invention provides a calibration device for an optical detector comprising a light emitting diode 1, and an electronic circuit 3 for driving the light emitting diode 1, wherein the electronic circuit 3 is a constant current generator configured to supply a constant driving current to the light emitting diode 1 in the range of 0.5 to 25 ?A. Furthermore, the present invention provides a setting device for setting at least one calibration point for a calibration device as described above. The setting device comprises a light detector 51 configured to output a signal representing the light emission intensity of a calibration device under examination, a controller 53 for controlling the constant driving current of the calibration device under examination, and a calibration point setting means 55 for setting at least one calibration point for the calibration device under examination.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: October 10, 2023
    Assignee: MERCK PATENT GmbH
    Inventors: Fabrice Comini, Frederick G. Bargoot, Victor Etre